133 related articles for article (PubMed ID: 32314800)
1. An oral, chemotherapy-free regimen (dasatinib plus prednisone) as induction and consolidation for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia.
Li XY; Qian JJ; Yang M; Zhang Y; Wang SS; Meng HT; Yu WJ; Tong HY; Ye XJ; Jin J; Zhu HH
Br J Haematol; 2020 Jun; 189(6):e231-e234. PubMed ID: 32314800
[No Abstract] [Full Text] [Related]
2. Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trial.
Hunger SP; Tran TH; Saha V; Devidas M; Valsecchi MG; Gastier-Foster JM; Cazzaniga G; Reshmi SC; Borowitz MJ; Moorman AV; Heerema NA; Carroll AJ; Martin-Regueira P; Loh ML; Raetz EA; Schultz KR; Slayton WB; Cario G; Schrappe M; Silverman LB; Biondi A
Lancet Haematol; 2023 Jul; 10(7):e510-e520. PubMed ID: 37407142
[TBL] [Abstract][Full Text] [Related]
3. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Ravandi F; O'Brien SM; Cortes JE; Thomas DM; Garris R; Faderl S; Burger JA; Rytting ME; Ferrajoli A; Wierda WG; Verstovsek S; Champlin R; Kebriaei P; McCue DA; Huang X; Jabbour E; Garcia-Manero G; Estrov Z; Kantarjian HM
Cancer; 2015 Dec; 121(23):4158-64. PubMed ID: 26308885
[TBL] [Abstract][Full Text] [Related]
4. Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.
Foà R; Bassan R; Vitale A; Elia L; Piciocchi A; Puzzolo MC; Canichella M; Viero P; Ferrara F; Lunghi M; Fabbiano F; Bonifacio M; Fracchiolla N; Di Bartolomeo P; Mancino A; De Propris MS; Vignetti M; Guarini A; Rambaldi A; Chiaretti S;
N Engl J Med; 2020 Oct; 383(17):1613-1623. PubMed ID: 33085860
[TBL] [Abstract][Full Text] [Related]
5. JSH practical guidelines for hematological malignancies, 2018: I. leukemia-3. acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL).
Hatta Y; Hayakawa F; Yamazaki E
Int J Hematol; 2020 Oct; 112(4):439-458. PubMed ID: 32812190
[No Abstract] [Full Text] [Related]
6. Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor.
Short NJ; Kantarjian HM; Sasaki K; Ravandi F; Ko H; Cameron Yin C; Garcia-Manero G; Cortes JE; Garris R; O'Brien SM; Patel K; Khouri M; Thomas D; Jain N; Kadia TM; Daver NG; Benton CB; Issa GC; Konopleva M; Jabbour E
Am J Hematol; 2017 Mar; 92(3):238-243. PubMed ID: 28006851
[TBL] [Abstract][Full Text] [Related]
7. Severe hypofibrinogenemia associated with imatinib and prednisone therapy in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Sciumè M; Fracchiolla NS; Cortelezzi A
Leuk Lymphoma; 2018 Oct; 59(10):2516-2517. PubMed ID: 29384412
[No Abstract] [Full Text] [Related]
8. Long-term follow-up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Lim SN; Joo YD; Lee KH; Kim DY; Lee JH; Lee JH; Chi HS; Yun SC; Lee WS; Lee SM; Park S; Kim I; Sohn SK; Moon JH; Ryoo HM; Bae SH; Hyun MS; Kim MK; Kim HJ; Yang DH; Eom HS; Lee GW; Jung CW; Won JH; Kim H; Lee JH; Shin HJ; Jang DY
Am J Hematol; 2015 Nov; 90(11):1013-20. PubMed ID: 26228525
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and prognostic factors of imatinib plus CALLG2008 protocol in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Lou Y; Ma Y; Li C; Suo S; Tong H; Qian W; Mai W; Meng H; Yu W; Mao L; Wei J; Xu W; Jin J
Front Med; 2017 Jun; 11(2):229-238. PubMed ID: 28349299
[TBL] [Abstract][Full Text] [Related]
10. Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
Xu N; Li YL; Li X; Zhou X; Cao R; Li H; Li L; Lu ZY; Huang JX; Fan ZP; Huang F; Zhou HS; Zhang S; Liu Z; Zhu HQ; Liu QF; Liu XL
J Hematol Oncol; 2016 Apr; 9():40. PubMed ID: 27090891
[TBL] [Abstract][Full Text] [Related]
11. Successful use of trametinib and dasatinib combined with chemotherapy in the treatment of Ph-positive B-cell acute lymphoblastic leukemia: A case report.
Wang J; Shen SH; Hu BF; Wang GL
Medicine (Baltimore); 2021 Jun; 100(25):e26440. PubMed ID: 34160436
[TBL] [Abstract][Full Text] [Related]
12. Philadelphia-positive acute lymphoblastic leukaemia (ALL) in Italy during the COVID-19 pandemic: a Campus ALL study.
Foà R; Bonifacio M; Chiaretti S; Curti A; Candoni A; Fava C; Ciccone M; Pizzolo G; Ferrara F
Br J Haematol; 2020 Jul; 190(1):e3-e5. PubMed ID: 32368790
[No Abstract] [Full Text] [Related]
13. Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Akahoshi Y; Nishiwaki S; Mizuta S; Ohashi K; Uchida N; Tanaka M; Fukuda T; Ozawa Y; Takahashi S; Onizuka M; Shiratori S; Nakamae H; Kanda Y; Ichinohe T; Atsuta Y; Kako S;
Cancer Sci; 2019 Oct; 110(10):3255-3266. PubMed ID: 31402561
[TBL] [Abstract][Full Text] [Related]
14. Effect of Dasatinib vs Imatinib in the Treatment of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
Shen S; Chen X; Cai J; Yu J; Gao J; Hu S; Zhai X; Liang C; Ju X; Jiang H; Jin R; Wu X; Wang N; Tian X; Pan K; Jiang H; Sun L; Fang Y; Li CK; Hu Q; Yang M; Zhu Y; Zhang H; Li C; Pei D; Jeha S; Yang JJ; Cheng C; Tang J; Zhu X; Pui CH
JAMA Oncol; 2020 Mar; 6(3):358-366. PubMed ID: 31944221
[TBL] [Abstract][Full Text] [Related]
15. Childhood Philadelphia-chromosome-positive B-lymphoblastic leukaemia.
Thomas D
Lancet Oncol; 2012 Sep; 13(9):860-2. PubMed ID: 22935232
[No Abstract] [Full Text] [Related]
16. Effects of conditioning intensity in allogeneic stem cell transplantation for Philadelphia chromosome‑positive acute lymphoblastic leukemia.
Takashima S; Miyamoto T; Kamimura T; Yoshimoto G; Yoshida S; Henzan H; Takase K; Kato K; Ito Y; Ohno Y; Nagafuji K; Eto T; Techima T; Akashi K
Int J Hematol; 2015 Dec; 102(6):689-96. PubMed ID: 26475283
[TBL] [Abstract][Full Text] [Related]
17. Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia.
King AC; Pappacena JJ; Tallman MS; Park JH; Geyer MB
Leuk Res; 2019 Apr; 79():27-33. PubMed ID: 30831480
[TBL] [Abstract][Full Text] [Related]
18. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Daver N; Thomas D; Ravandi F; Cortes J; Garris R; Jabbour E; Garcia-Manero G; Borthakur G; Kadia T; Rytting M; Konopleva M; Kantarjian H; O'Brien S
Haematologica; 2015 May; 100(5):653-61. PubMed ID: 25682595
[TBL] [Abstract][Full Text] [Related]
19. Combination chemotherapy plus dasatinib leads to comparable overall survival and relapse-free survival rates as allogeneic hematopoietic stem cell transplantation in Philadelphia positive acute lymphoblastic leukemia.
Chang J; Douer D; Aldoss I; Vahdani G; Jeong AR; Ghaznavi Z; Zhang S; Yaghmour G; Lee KJ; Weissman A; Akhtari M
Cancer Med; 2019 Jun; 8(6):2832-2839. PubMed ID: 31016870
[TBL] [Abstract][Full Text] [Related]
20. Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622.
Slayton WB; Schultz KR; Kairalla JA; Devidas M; Mi X; Pulsipher MA; Chang BH; Mullighan C; Iacobucci I; Silverman LB; Borowitz MJ; Carroll AJ; Heerema NA; Gastier-Foster JM; Wood BL; Mizrahy SL; Merchant T; Brown VI; Sieger L; Siegel MJ; Raetz EA; Winick NJ; Loh ML; Carroll WL; Hunger SP
J Clin Oncol; 2018 Aug; 36(22):2306-2314. PubMed ID: 29812996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
